Skip to main content
Frontiers in Cardiovascular Medicine logoLink to Frontiers in Cardiovascular Medicine
. 2022 Dec 5;9:1076420. doi: 10.3389/fcvm.2022.1076420

Corrigendum: Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants

Hongjie Chen 1, Jiepeng Chen 2, Fuping Zhang 3, Yuanhui Li 4, Ronghua Wang 2, Qiang Zheng 2, Xu Zhang 2, Jun Zeng 2, Feng Xu 5,*, Yiguang Lin 1,6,7,*
PMCID: PMC9761765  PMID: 36545015

In the published article, there was an error in Table 1 Baseline characteristics of the participants as published.

Table 1.

Baseline characteristics of the participants.

Age (year) 67.5 (63–85)
Gender
Male 491
Female 571
Exercise
<5,000 steps/d 356
>5,000 steps/d 706
BMI
<27.5 980
>27.5 82
Smoker 259
Alcohol drinking
<100 ml/w 799
>100 ml/w 263
Vitamin K2 co-admin (180 μg/d) 181
Aspirin co-admin (100 mg/d) 96
Hyperlipidemia 1,062
Atherosclerosis 683

The corrected Table and correct format appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Cardiovascular Medicine are provided here courtesy of Frontiers Media SA

RESOURCES